Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, June 20, 2019
[ Thu, Jun 20th 2019
] - WOPRAI
Wed, June 19, 2019
[ Wed, Jun 19th 2019
] - WOPRAI
[ Wed, Jun 19th 2019
] - WOPRAI
[ Wed, Jun 19th 2019
] - WOPRAI
[ Wed, Jun 19th 2019
] - WOPRAI
[ Wed, Jun 19th 2019
] - WOPRAI
[ Wed, Jun 19th 2019
] - WOPRAI
[ Wed, Jun 19th 2019
] - WOPRAI
Tue, June 18, 2019
[ Tue, Jun 18th 2019
] - WOPRAI
[ Tue, Jun 18th 2019
] - WOPRAI
[ Tue, Jun 18th 2019
] - WOPRAI
[ Tue, Jun 18th 2019
] - WOPRAI
[ Tue, Jun 18th 2019
] - WOPRAI
[ Tue, Jun 18th 2019
] - WOPRAI
[ Tue, Jun 18th 2019
] - WOPRAI
[ Tue, Jun 18th 2019
] - WOPRAI
[ Tue, Jun 18th 2019
] - WOPRAI
[ Tue, Jun 18th 2019
] - WOPRAI
[ Tue, Jun 18th 2019
] - WOPRAI
[ Tue, Jun 18th 2019
] - WOPRAI
[ Tue, Jun 18th 2019
] - WOPRAI
Mon, June 17, 2019
[ Mon, Jun 17th 2019
] - WOPRAI
[ Mon, Jun 17th 2019
] - WOPRAI
[ Mon, Jun 17th 2019
] - WOPRAI
Matthew Luchini Maintained (BLUE) at Buy with Decreased Target to $163 on, Jun 17th, 2019
Matthew Luchini of BMO Capital, Maintained "bluebird bio, Inc." (BLUE) at Buy with Decreased Target from $191 to $163 on, Jun 17th, 2019.
Matthew has made no other calls on BLUE in the last 4 months.
There are 2 other peers that have a rating on BLUE. Out of the 2 peers that are also analyzing BLUE, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Michael Schmidt of "Leerink Swann" Downgraded from Buy to Hold on, Tuesday, March 5th, 2019
This is the rating of the analyst that currently disagrees with Matthew
- Yaron Werber of "Cowen & Co." Initiated at Buy on, Tuesday, February 26th, 2019
